As targeted therapies for nonalcoholic steatohepatitis (NASH) are approved for clinical use, managed care pharmacists will be challenged to make evidence-based treatment decisions for patients with NASH that improve patient outcomes and optimize health care resources. The aim of this interactive symposium is to help prepare managed care pharmacists for this important role. Expert faculty will discuss the morbidity, mortality and other costs of not treating patients with clinically significant fibrosis, which patients will be the likely candidates for targeted therapies for NASH and how to identify them, and the current status of clinical trials of these therapies.
ReachMD
Be part of the knowledge.™Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
NASH: An Epidemic with Significant Implications for Managed Care Professionals
Do you understand your role in determining which patient may benefit the most from NASH therapy?
Live
Meeting
1.50 available credits
Information
October 18, 2023
06:00 PM - 08:00 PM EDT
Orlando World Center Marriott
8701 World Center Drive, Room: Canary 3 and 4, Orlando, Florida, United States
Share
Share
Share
Share this program on:
Details
Presenters
Related
Comments
Overview
Program Schedule
- 6:00pm – 6:30pm: Registration & Dinner
- 6:30pm – 6:55pm: Defining the Epidemic and Treating NASH: The Value Proposition
- 6:55pm – 7:20pm: Practice Guidelines and Clinical Care Pathway for NAFLD and the Current Standard of Care
- 7:20pm – 7:40pm: Emerging Therapies: Updates on Phase 3 Trials
- 7:40pm – 7:50pm: Implications of the Approval of a Liver-Directed, NASH-Specific Therapy
- 7:50pm – 8:00pm: Closing Remarks and Audience Q&A
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Host:
Zobair M. Younossi, MD, MPH, FACP, FACG, AGAF, FAASLD
President, Inova Medicine Services
Chairman, Clinical Research, Inova Health System
Professor & Chairman, Department of Medicine
Inova Fairfax Medical Campus
Falls Church, VAConsultant: Abbvie, Bristol Myers Squibb, Genfit, Gilead Sciences, Intercept, Madrigal, Merck, Novo Nordisk, Siemens, Terns Pharmaceuticals, Inc., Viking Therapeutics
Faculty:
Naim Alkhouri, MD, FAASLD
Chief Medical Officer
Director, Fatty Liver Program
Chief, Transplant Hepatology
Arizona Liver Health
Phoenix, AZConsulting Fees: 89Bio, AbbVie/Allergan, Echosens, Fibronostics, Gilead, Intercept, Madrigal Pharmaceuticals, Novo Nordisk, Perspectum, Pfizer, Zydus
Research: 89Bio, AbbVie/Allergan, Akero, Better Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Corcept, DSM, Galectin, Genentech, Genfit, Gilead, Hepagene, Healio, Intercept, Inventiva, Ionis, Madrigal Pharmaceuticals, Merck, NGM, Noom, NorthSea, Novo Nordisk, Perspectum, Pfizer, Poxel, Viking, Zydus
Kathleen E. Corey, MD, MPH
Director, MGH Fatty Liver Program
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, MAConsulting Fees: Intercept, Theratechnologies
Reviewers/Content Planners/Authors:
- Cindy Davidson has nothing to disclose.
- Elizabeth Lurwick has nothing to disclose.
- John Maeglin has nothing to disclose.
- Andrea Mathis has nothing to disclose.
- Tim Person has nothing to disclose.
- Colleen Resnick has nothing to disclose.
- Susan Smith, MN, PhD, has ownership interest in Hepion Pharmaceuticals.
- Brian P. McDonough, MD, FAAFP, has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Summarize the morbidity and mortality associated with advanced fibrosis
- Compare the known costs of not treating advanced fibrosis with the estimated cost of treating nonalcoholic steatohepatitis (NASH) with a new liver-directed therapy
- Select patients who meet the likely indications for treatment of NASH with new liver-directed therapy
Target Audience
This activity is designed to meet the educational needs of pharmacists, physicians, nurse practitioners, and physician associates.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.5 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.5 contact hours/0.15 CEUs of pharmacy contact hours.The Universal Activity Number for this program is JA0006235-0000-23-044-L01-P. This learning activity is live. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
Provider(s)/Educational Partner(s)
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.
Commercial Support
This activity is supported by an independent educational grant from Madrigal Pharmaceuticals.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.ADA Description
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Andrea Mathis prior to the live event at amathis@glc.healthcare.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Presenters
Details
Presenters
Related
Comments
Recommended
Overview
As targeted therapies for nonalcoholic steatohepatitis (NASH) are approved for clinical use, managed care pharmacists will be challenged to make evidence-based treatment decisions for patients with NASH that improve patient outcomes and optimize health care resources. The aim of this interactive symposium is to help prepare managed care pharmacists for this important role. Expert faculty will discuss the morbidity, mortality and other costs of not treating patients with clinically significant fibrosis, which patients will be the likely candidates for targeted therapies for NASH and how to identify them, and the current status of clinical trials of these therapies.
Program Schedule
- 6:00pm – 6:30pm: Registration & Dinner
- 6:30pm – 6:55pm: Defining the Epidemic and Treating NASH: The Value Proposition
- 6:55pm – 7:20pm: Practice Guidelines and Clinical Care Pathway for NAFLD and the Current Standard of Care
- 7:20pm – 7:40pm: Emerging Therapies: Updates on Phase 3 Trials
- 7:40pm – 7:50pm: Implications of the Approval of a Liver-Directed, NASH-Specific Therapy
- 7:50pm – 8:00pm: Closing Remarks and Audience Q&A
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Host:
Zobair M. Younossi, MD, MPH, FACP, FACG, AGAF, FAASLD
President, Inova Medicine Services
Chairman, Clinical Research, Inova Health System
Professor & Chairman, Department of Medicine
Inova Fairfax Medical Campus
Falls Church, VAConsultant: Abbvie, Bristol Myers Squibb, Genfit, Gilead Sciences, Intercept, Madrigal, Merck, Novo Nordisk, Siemens, Terns Pharmaceuticals, Inc., Viking Therapeutics
Faculty:
Naim Alkhouri, MD, FAASLD
Chief Medical Officer
Director, Fatty Liver Program
Chief, Transplant Hepatology
Arizona Liver Health
Phoenix, AZConsulting Fees: 89Bio, AbbVie/Allergan, Echosens, Fibronostics, Gilead, Intercept, Madrigal Pharmaceuticals, Novo Nordisk, Perspectum, Pfizer, Zydus
Research: 89Bio, AbbVie/Allergan, Akero, Better Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Corcept, DSM, Galectin, Genentech, Genfit, Gilead, Hepagene, Healio, Intercept, Inventiva, Ionis, Madrigal Pharmaceuticals, Merck, NGM, Noom, NorthSea, Novo Nordisk, Perspectum, Pfizer, Poxel, Viking, Zydus
Kathleen E. Corey, MD, MPH
Director, MGH Fatty Liver Program
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, MAConsulting Fees: Intercept, Theratechnologies
Reviewers/Content Planners/Authors:
- Cindy Davidson has nothing to disclose.
- Elizabeth Lurwick has nothing to disclose.
- John Maeglin has nothing to disclose.
- Andrea Mathis has nothing to disclose.
- Tim Person has nothing to disclose.
- Colleen Resnick has nothing to disclose.
- Susan Smith, MN, PhD, has ownership interest in Hepion Pharmaceuticals.
- Brian P. McDonough, MD, FAAFP, has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Summarize the morbidity and mortality associated with advanced fibrosis
- Compare the known costs of not treating advanced fibrosis with the estimated cost of treating nonalcoholic steatohepatitis (NASH) with a new liver-directed therapy
- Select patients who meet the likely indications for treatment of NASH with new liver-directed therapy
Target Audience
This activity is designed to meet the educational needs of pharmacists, physicians, nurse practitioners, and physician associates.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.5 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should claim only the credit commensurate with the extent of their participation in the activity.Global Learning Collaborative (GLC) designates this activity for 1.5 contact hours/0.15 CEUs of pharmacy contact hours.The Universal Activity Number for this program is JA0006235-0000-23-044-L01-P. This learning activity is live. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
Provider(s)/Educational Partner(s)
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.
Commercial Support
This activity is supported by an independent educational grant from Madrigal Pharmaceuticals.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.ADA Description
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Andrea Mathis prior to the live event at amathis@glc.healthcare.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Presenters
Facebook Comments